Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia

Jill Samis; Paul Lee; Donald Zimmerman; Robert J. Arceci; Meinolf Suttorp; Nobuko Hijiya

doi:10.1002/pbc.26028

Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia

Jill Samis, Paul Lee, Donald Zimmerman, Robert J. Arceci, Meinolf Suttorp, Nobuko Hijiya

School of Medicine

Research output: Contribution to journal › Review article › peer-review

31 Scopus citations

Abstract

Side effects of tyrosine kinase inhibitor (TKI) treatment vary in children and adults with chronic myelogenous leukemia (CML). As children have a much longer life expectancy than adults, TKI therapy may continue for decades and with long-term consequences that differ from adults. Children may develop endocrinopathies related to “off-target” effects of TKIs, such as delayed growth, changes in bone metabolism, thyroid abnormalities, and effects on puberty and fertility. These endocrinopathies present additional challenges for pediatric patients with CML. This review critically evaluates the literature on long-term endocrine side effects of TKIs in the pediatric CML population and provides suggested recommendations.

Original language	English (US)
Pages (from-to)	1332-1338
Number of pages	7
Journal	Pediatric Blood and Cancer
Volume	63
Issue number	8
DOIs	https://doi.org/10.1002/pbc.26028
State	Published - Aug 1 2016

Keywords

CML
TKI
children
endocrine
growth

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.26028

Cite this

@article{3581152d7a1c4263946e1aef0b725223,

title = "Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia",

abstract = "Side effects of tyrosine kinase inhibitor (TKI) treatment vary in children and adults with chronic myelogenous leukemia (CML). As children have a much longer life expectancy than adults, TKI therapy may continue for decades and with long-term consequences that differ from adults. Children may develop endocrinopathies related to “off-target” effects of TKIs, such as delayed growth, changes in bone metabolism, thyroid abnormalities, and effects on puberty and fertility. These endocrinopathies present additional challenges for pediatric patients with CML. This review critically evaluates the literature on long-term endocrine side effects of TKIs in the pediatric CML population and provides suggested recommendations.",

keywords = "CML, TKI, children, endocrine, growth",

author = "Jill Samis and Paul Lee and Donald Zimmerman and Arceci, {Robert J.} and Meinolf Suttorp and Nobuko Hijiya",

note = "Publisher Copyright: {\textcopyright} 2016 Wiley Periodicals, Inc.",

year = "2016",

month = aug,

day = "1",

doi = "10.1002/pbc.26028",

language = "English (US)",

volume = "63",

pages = "1332--1338",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "8",

}

TY - JOUR

T1 - Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia

AU - Samis, Jill

AU - Lee, Paul

AU - Zimmerman, Donald

AU - Arceci, Robert J.

AU - Suttorp, Meinolf

AU - Hijiya, Nobuko

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Side effects of tyrosine kinase inhibitor (TKI) treatment vary in children and adults with chronic myelogenous leukemia (CML). As children have a much longer life expectancy than adults, TKI therapy may continue for decades and with long-term consequences that differ from adults. Children may develop endocrinopathies related to “off-target” effects of TKIs, such as delayed growth, changes in bone metabolism, thyroid abnormalities, and effects on puberty and fertility. These endocrinopathies present additional challenges for pediatric patients with CML. This review critically evaluates the literature on long-term endocrine side effects of TKIs in the pediatric CML population and provides suggested recommendations.

AB - Side effects of tyrosine kinase inhibitor (TKI) treatment vary in children and adults with chronic myelogenous leukemia (CML). As children have a much longer life expectancy than adults, TKI therapy may continue for decades and with long-term consequences that differ from adults. Children may develop endocrinopathies related to “off-target” effects of TKIs, such as delayed growth, changes in bone metabolism, thyroid abnormalities, and effects on puberty and fertility. These endocrinopathies present additional challenges for pediatric patients with CML. This review critically evaluates the literature on long-term endocrine side effects of TKIs in the pediatric CML population and provides suggested recommendations.

KW - CML

KW - TKI

KW - children

KW - endocrine

KW - growth

UR - http://www.scopus.com/inward/record.url?scp=84976474984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976474984&partnerID=8YFLogxK

U2 - 10.1002/pbc.26028

DO - 10.1002/pbc.26028

M3 - Review article

C2 - 27100618

AN - SCOPUS:84976474984

SN - 1545-5009

VL - 63

SP - 1332

EP - 1338

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 8

ER -

Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this